A examine posted in JAMA Network Open up emphasizes the discrepancy involving what it fees to make copyright and the retail selling prices clients deal with. Despite the small output expenditures, Novo Nordisk has not publicly disclosed distinct figures for copyright or its other products, Wegovy.California biotech behemoth Amgen ditched options fo